

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10655889	
	Filing Date		2003-09-04	
	First Named Inventor	Schmidt, Richard A.		
	Art Unit	1651		
	Examiner Name	Afremova, Vera		
	Attorney Docket Number	5662-1-PUS-1-1		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5437291		1995-08-01	Pasricha, et al.			
	2	4932936		1990-06-12	Dykstra et al.			
	3	5183462		1993-02-02	Borodic			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20050048084		2005-03-03	Schmidt, Richard A.			
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	6-183975	JP		1994-07-05	LILLY CO ELI	Abstract in English	<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10655889
Filing Date	2003-09-04
First Named Inventor	Schmidt, Richard A.
Art Unit	1651
Examiner Name	Afremova, Vera
Attorney Docket Number	5662-1-PUS-1-1

2	WO 95/17904			1995-07-06	Aoki et al.		<input type="checkbox"/>
---	-------------	--	--	------------	-------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	AMARENCO, Pour la pratique, Lae Revue du Praticien (Paris), 1995, 343-345, 45, FRANCE and abstract in English	<input checked="" type="checkbox"/>
	2	ARAKI et al. Detrusor-Sphincter Dyssynergia with Special Reference to its Diagnosis and Treatment, J. Saitama Med. School, 1992, 23-27, Vol. 19, Department of Urology, Saitama Medical School, Moroyama, Iruma-gun, Saitama, JAPAN	<input type="checkbox"/>
	3	BULAU, Therapeutische Perspektiven mit Botulinumtoxin Type A., Neurologie und rehabilitation, 1997, 55-56, GERMANY	<input type="checkbox"/>
	4	DOGGWEILER et al., Botox-Induced Prostatic Involution, The Prostate, 1998, 44-50, Vol. 37, University of Colorado Health Science Center, Denver, CO, USA	<input type="checkbox"/>
	5	DYKSTRA et al., Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients, J Urol, May 1998, 919-922, Vol. 139, Departments of Physical Medicine and Rehabilitation and Urologic Surgery, University of Minnesota Hospital and Clinic, Minneapolis Minnesota, USA	<input type="checkbox"/>
	6	FOWLER et al., Mytonic-Like EMG Activity of the Urethral Sphincter in Women with Urinary Retention and the Use of Botulinum Toxin to Treat this Disorder, Neurophysiologie Clinique, 1990, 19s, Vol. 20, Department of Uro-Neurology, National Hospital for Nervous Diseases, Queen Square and Urology Departments, The London Hospital and the Middlesex Hospital UNITED KINGDOM	<input type="checkbox"/>
	7	FOWLER et al., Botulinum Toxin in the Treatment of Chronic Urinary Retention in Women, British Journal of Urology, 1992, 387-389, Vol. 70, British Journal of Urology, UNITED KINGDOM	<input type="checkbox"/>
	8	MARIA et al., Relief by botulinum toxin of voiding dysfunction due to prostatitis, LANCET (North American Edition), 1998, 625, Vol. 352, Departments of Surgery, Urology and Neurology, Catholic University of Rome, Rome, USA	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10655889
Filing Date	2003-09-04
First Named Inventor	Schmidt, Richard A.
Art Unit	1651
Examiner Name	Afremova, Vera
Attorney Docket Number	5662-1-PUS-1-1

9	HARRISON, Principles of Internal Medicine, 1987, 196-197, 11th Edition, McGraw-Hill Book Company, New York, New York, USA	<input type="checkbox"/>
10	JANKOVIC, Botulinum toxin in movement disorders, Current Opinion in Neurology, 1994, 358-366, Vol. 7, Baylor College of Medicine, Houston, Texas, USA	<input type="checkbox"/>
11	JANKOVIC, Therapeutic uses of Botulinum, The New England Journal of Medicine, 1991, 1186-1194, Vol. 324 No. 17, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA	<input type="checkbox"/>
12	KARP, et al., Therapeutic Effects of Botulinum Toxins, Handbook of Natural Toxins; Bacterial Toxins and Virulence Factors in Disease, 1995, 1-22, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA	<input type="checkbox"/>
13	PUNCH, Gynaecological, and non-gynaecological, chronic pelvic pain, The Lancet, February 21, 1998, 607, Vol. 351, Department of OB/BYN, University of Michigan Medical Center, Women's Hospital, Ann Arbor, Michigan, USA	<input type="checkbox"/>
14	STEINHARDT et al., Botulinum Toxin Novel Treatment for Dramatic Urethral Dilation Associated with Dysfunctional Voiding, The Journal of Urology, 1997, 190-191, Vol. 158, American Urological Association, Inc., St. Louis, Missouri, USA	<input type="checkbox"/>
15	ZWERGEL, et al. "Bladder Dysfunction in Disseminated Encephalomyelitis-Drug Therapy and Interventional Methods, Fortschritte Der Neurologie Psychiatrie, 1995, 495-503, Vol. 63, Neurologische Klinik der Universitat des Saarlandes, Homburg/Saar, GERMANY	<input type="checkbox"/>
16	GRISE, PHILLIPPE, Affidavit, September 26, 2006	<input type="checkbox"/>
17	GROSSE, JOACHIM, Affidavit, September 25, 2006	<input type="checkbox"/>
18	CARL, STEFAN, Affidavit, September 26, 2006	<input type="checkbox"/>
19	E. Shapiro et al., "Quantifying the Smooth Muscle Content of the Prostate...", The Journal of Urology 147 (1992), pages 1167 to 1170	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10655889
Filing Date	2003-09-04
First Named Inventor	Schmidt, Richard A.
Art Unit	1651
Examiner Name	Afremova, Vera
Attorney Docket Number	5662-1-PUS-1-1

20	G.E. Borodic and L.B. Pearce, "New Concepts in Botulinum Toxin Therapy", Drug Safety 11 (1994), pages145-152	<input type="checkbox"/>
21	Internet presentation on prostate disorders and the anatomy of the prostate/bladder: http://www.familydoctor.co.uk/htdocs/PROSTATE/PROSTATE_specimen.html (printed on December 11, 2006)	<input type="checkbox"/>
22	Internet presentation on prostatitis: http://www.urology-health.org/adult/index.cfm?cat=07&topic=15 (printed on December 11, 2006)	<input type="checkbox"/>
23	Entry for "benigne Prostatahyperplasie" in Pschyrembel, klinisches Worterbuch (257.Auflage, 1994)	<input type="checkbox"/>
24	Martinez Pinero et al., "Pelvic Plexus Denervation in Rats Causes Morphologic and Functional Changes of the Prostate", The Journal of Urology 150 (1993), pages 215-218	<input type="checkbox"/>
25	Amerenco, "Evaluation et Traitment des Dysfoctionnements Vesico-Sphincteriens Neurogenes" Annales d'Urologie 27 (1993) pages 313-320	<input checked="" type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10655889
Filing Date	2003-09-04
First Named Inventor	Schmidt, Richard A.
Art Unit	1651
Examiner Name	Afremova, Vera
Attorney Docket Number	5662-1-PUS-1-1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Darla G. Yoerg/	Date (YYYY-MM-DD)	2007-04-10
Name/Print	Darla G. Yoerg	Registration Number	48053

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.